ICU Medical sees FY25 EPS $6.55-$7.25, consensus $7.13

For fiscal year 2025 the Company estimates GAAP net loss to be in the range of $(45) million to $(28) million and GAAP net loss per share estimated to be in the range of $(1.81) to $(1.11). For the fiscal year 2025, excluding the potential impact from the Company’s previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395M to $425M , and adjusted EPS to be in the range of $6.55 to $7.25. The Company anticipates the IV Solutions joint venture will close during the second quarter of 2025 and, if so, is expected to reduce the 2025 adjusted EBITDA guidance by $15 million to $20 million and be neutral to adjusted EPS.